If you can do the mental work to separate your sentiment about a stock from its recent price action, buying the dip in a recently dented winner can be a profitable investing strategy. Of course, it's key that you determine whether a business is experiencing a temporary setback or a more durable downturn before making the decision to buy. That can make the difference between buying the dip and making more money later, and buying the dip only to see your investment's value decline further. What's causing the ...

文章核心观点 - 该公司在2023年11月29日至2024年3月22日期间的证券交易中存在虚假陈述和重大遗漏 [1][5] - 公司误导性地夸大了其获得美国林业局2024年火灾季节续约合同的可能性,因为其消防阻燃剂存在安全隐患 [5] - 公司对其消防阻燃剂安全性的测试结果存在严重夸大 [5] - 上述行为导致公司的业务、运营和前景陈述存在重大虚假和误导性 [5] 公司相关 - 公司名称为Compass Minerals International, Inc. [1] - 公司股票代码为NYSE: CMP [1] - 公司主要从事消防阻燃剂业务 [5] - 公司与美国林业局存在合作关系,提供专有的氯化镁基消防阻燃剂 [5] 投资者权益 - 投资者可以在2024年6月24日之前加入集体诉讼 [1][3] - 投资者无需支付任何费用即可获得赔偿,采用或有费用安排 [2] - 投资者可以选择合适的律师代表自己参与诉讼 [7] - 即使不担任首席原告,投资者也可以分享潜在的赔付 [7]

https://zlk.com/pslra-1/compass-minerals-lawsuit-submission-form?prid=83082&wire=3 CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Compass Minerals overstated the likelihood that it would be awarded a renewed U.S. Forest Service contract for the use of its proprietary magnesium chloride-based aerial fire retardants for the 2024 fire season, as a result of safety issues presented by its fire retardant; (2) Compass Minerals materially overstated the e ...

文章核心观点 - Compass Minerals International, Inc. (Compass Minerals) 的投资者因公司虚假陈述和隐瞒信息而遭受损失，已提起集体诉讼 [1][3] 投资者行动 - 投资者在2023年11月29日至2024年3月22日期间购买和/或出售股票的，鼓励联系律师Lesley F. Portnoy讨论法律权利 [2] - 投资者可以通过www.portnoylaw.com加入案件，Portnoy Law Firm提供免费案件评估和讨论投资者的索赔选项 [2] 公司虚假陈述 - Compass Minerals夸大了其获得美国林业局2024年火灾季节合同的可能性，因其防火剂存在安全问题 [3] - 公司夸大了其防火剂安全性的测试结果 [3] - 公司的业务、运营和前景声明在所有时间点上都存在实质性的虚假和误导性 [3]

On this news, Compass's stock price fell $3.00 per share, or 17.09%, to close at $14.55 per share on March 25, 2024. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz c ...

On this news, the price of Compass Minerals stock fell $3.00 per share, or 17.09%, to close at $14.55 on March 25, 2024. The next day, Compass Minerals stock fell a further $0.86 per share, or 5.9%, to close at $13.69. NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Compass Minerals International, Inc. ("Compass Minerals" or the "Company") (NYSE: CMP) and reminds investors of the June 24, 2024 deadline to see ...

文章核心观点 - Compass Minerals International, Inc. (NYSE: CMP)的股东在特定期间购买的股票可能受到误导性陈述的影响，导致潜在的损失 [3] 相关目录 股东行动 - 股东在2023年11月29日至2024年3月22日期间购买CMP股票的，鼓励联系Gross Law Firm以可能成为首席原告 [2][3] - 首席原告任命不是参与任何恢复的必要条件 [2] - 股东应在2024年6月24日前注册参与集体诉讼 [4] - 注册后，股东将被纳入投资组合监控软件，以获取案件状态更新 [4] 指控内容 - Compass Minerals在2024年火灾季节获得美国森林服务合同的可能性被夸大，因其防火剂存在安全问题 [3] - Compass Minerals对其防火剂安全性的测试结果被夸大 [3] - 因此，公司关于其业务、运营和前景的陈述在所有时间点都是虚假和误导性的，或缺乏合理基础 [3] 法律服务 - Gross Law Firm是一家全国公认的集体诉讼律师事务所，致力于保护因欺骗、欺诈和非法商业行为而遭受损失的投资者的权利 [5] - 该律师事务所致力于确保公司遵守负责任的商业实践和良好的企业公民身份 [5] - 该律师事务所寻求为因公司虚假和/或误导性陈述或遗漏重要信息而导致股票人为上涨的投资者追回损失 [5]

Fort Lauderdale, Florida--(Newsfile Corp. - May 30, 2024) - Flora Growth Corp. (NASDAQ: FLGC) ("Flora" or the "Company")'s Vessel Brand ("Vessel"), renowned for its design and precision craftsmanship, proudly announces the release of Compass Rise. Built for the discerning connoisseur, Compass Rise embodies sophistication while delivering what consumers have come to expect from Vessel's products. From its sleek design, cutting-edge technology, and the ability to stay upright, every aspect of Compass Rise ref ...

BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinicalstage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place in New York City, NY June 5 – 6, 2024. Fireside Chat details Date: Wednesday, June 5, 2024 Time: 1:00 – 1:25 PM ET Webcast Link: https://wsw.com/jefferiesw ...

BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinicalstage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its Board of Directors has appointed Thomas Schuetz, M.D., Ph.D., President of Research and Development and Vice Chair of the Board of Directors of the Company, as President and Chief Executive Officer of the Company, effective May 28, 2024. Vered Bisker-Leib, P ...